24小时热门版块排行榜    

查看: 650  |  回复: 4
【奖励】 本帖被评价3次,作者wangye增加金币 2
当前主题已经存档。

wangye

禁言 (正式写手)


[资源] Statistics In Drug Research

Statistics In Drug Research: Methodologies and Recent Developments (Biostatistics, 10)
By Shein-Chung Chow

Publisher:   CRC
Number Of Pages:   367
Publication Date:   2002
Sales Rank:   1460072
ISBN / ASIN:   082470763X
EAN:   9780824707637
Binding:   Hardcover
Manufacturer:   CRC
Studio:   CRC
Average Rating:   5



Emphasizing the role of good statistical practices (GSP) in drug research and formulation, this book outlines important statistics applications for each stage of pharmaceutical development to ensure the valid design, analysis, and assessment of drug products under investigation and establish the safety and efficacy of pharmaceutical compounds. Coverage include statistical techniques for assay validation and evaluation of drug performance characteristics, testing population/individual bioequivalence and in vitro bioequivalence according to the most recent FDA guidelines, basic considerations for the design and analysis of therapeutic equivalence and noninferiority trials.


Review:

belongs on desk of every pharmaceutical biostatistician

This is a very new and unique book that covers the gamut of statistical issues through all phases of drug development. Shao is a distinguished professor from Wisconsin and Chow teaches at Temple but is known for his long career in the pharmaceutical industry.

The book is good for biostatisticians and regulatory affairs specialists as a reference source. All the key statistical issues are addressed and the reader is given the perspective of the ICH and FDA guidance documents. The underlying statistical methodology that justifies the recommendations in the guidances is presented. This is a state-of-the-art book. Shao and Pigeot produced some of the recent research in individual bioequivalence that established a bootstrap procedure as an appropriate way to construct confidence intervals for the problem. Their method is recommended in an FDA guidance document.

But more than just this one example, all the key issues that have been the subject of FDA workshops over the past several years are addressed in this book. These topics include calibration, assay and assay validation, dissolution testing, stability analysis, shelf life estimation, bioequivalence, randomization and blinding, what constitutes substantive evidence in clinical development, therapeutic equivalence and noninferiority, Bayesian approaches in clinical trials, problems involving missing and incomplete data, longitudinal methods, meta-analysis, quality of life studies and instrument validation, and medical imaging.

Other prevalent issues in clinical trials include group sequential methods, hierarchical Bayesian models and multiple testing. These issues are not covered as much in this text as the others we have mentioned. But there is some discussion of multiplicity in the context of quality of life studies. An example of sequential testing is used to illustrate model selection in Chapter 2. The important issues of design and sample size requirements are presented throughout the book.

While not all topics are covered in sufficient depth, the book is remarkable in the breadth of material covered in just 350 pages of text. The authors also provide a very authoritative list of references and regulatory guidances and other documents.pass: gigapedia.org



http://mihd.net/r6ko87

http://rapidshare.com/files/6271 ... arch_082470763X.rar
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

yjhorn

木虫 (正式写手)


★★★ 三星级,支持鼓励

password may be wrong!
2楼2007-10-18 14:47:28
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

yinjj

金虫 (职业作家)


★★★★★ 五星级,优秀推荐

3楼2007-10-18 19:23:13
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

lubenle

至尊木虫 (职业作家)


无法下载?请指教!
4楼2007-10-19 15:03:58
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 wangye 的主题更新
☆ 无星级 ★ 一星级 ★★★ 三星级 ★★★★★ 五星级
普通表情 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 面上项目filecode邪修 +4 西山十月 2026-08-09 6/300 2026-08-10 00:16 by liufeng0619
[基金申请] 应该是93bebmhtak前后十一个字符比较关键 +7 Lanmanbaby 2026-08-09 14/700 2026-08-09 23:33 by Tide man
[基金申请] 2026国自然放榜时间 +4 布布和一二 2026-08-08 4/200 2026-08-09 22:24 by otj2008
[基金申请] 关于代码变化问题,想知道的进来 +15 且听虎啸 2026-08-07 22/1100 2026-08-09 22:13 by 布布和一二
[基金申请] 这样的filecode谁见过 +10 布布和一二 2026-08-08 21/1050 2026-08-09 17:21 by 天神眷顾
[基金申请] filecode与中标关系的预测 +5 布布和一二 2026-08-07 5/250 2026-08-09 16:15 by 袁向阳007
[基金申请] 关于filecode,很负责任的告诉大家 +6 爱看书的可乐 2026-08-08 7/350 2026-08-08 22:13 by a_niu
[考博] 【2027博士申请】纳米药物递送方向 20+3 13586093586 2026-08-03 5/250 2026-08-08 21:54 by 13586093586
[基金申请] 国基金的申报应该改成非等额制,评价高的钱多评价低的钱少,但是增加资助率 +7 a089 2026-08-07 7/350 2026-08-08 18:05 by gltch
[基金申请] 好奇怪的filecode +3 布布和一二 2026-08-08 4/200 2026-08-08 17:46 by zhanghaozhu
[基金申请] 关于filecode +4 布布和一二 2026-08-07 7/350 2026-08-07 22:55 by zhanghaozhu
[基金申请] 固定端突然变了,今天 +6 archvillain 2026-08-06 10/500 2026-08-07 16:03 by 医学老男孩
[基金申请] filecode变化情况 +6 布布和一二 2026-08-07 22/1100 2026-08-07 14:45 by 且听虎啸
[基金申请] 大家散了吧,后缀研究没有意义,别浪费时间了,过好目前的每一天,不要焦虑 +5 Tide man 2026-08-06 7/350 2026-08-07 13:11 by 医学老男孩
[基金申请] filecode +14 等待解的谜 2026-08-06 19/950 2026-08-07 12:20 by wlwhappy
[基金申请] filecode +8 布布和一二 2026-08-06 11/550 2026-08-06 20:41 by tangpu318
[基金申请] 求各位大神看下 100+6 hpkpkpkp 2026-08-05 33/1650 2026-08-06 14:49 by zhiyanjiang
[基金申请] 好消息?这个有何含义??? +8 Tide man 2026-08-05 10/500 2026-08-05 16:14 by xmuxiaoyu
[基金申请] 有没有H口的?有收到消息的吗? +3 超级海虾 2026-08-04 3/150 2026-08-04 17:26 by 学教育滴
[基金申请] 纯娱乐,不喜欢勿喷 +7 Tide man 2026-08-04 10/500 2026-08-04 15:10 by loufangrui
信息提示
请填处理意见